Athersys Stock News

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (OTC: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announced financial results f

Longevity stocks have started to come on many investors' radars. These companies come with the promise of stable returns over the long run as human life continues to stretch further ahead.

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX), (“Athersys” or the “Company”) a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical ca

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announces that the ind

CLEVELAND & LEXINGTON, Ky.--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, and M

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announces changes to its Board of Direc

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announces that Dr. Sam

The traditional approach to investing is finding well-established companies, investing in them and waiting years for a return of 50%. But in today's fast-paced stock market, retail traders are finding

Penny stocks, often priced under $1, have long been the allure for many investors seeking high-risk, high-reward opportunities. These stocks, typically from smaller companies, offer the tantalizing po

Athersys (NASDAQ: ATHX ) stock is falling on Friday after the biotechnology company announced a public stock offering. That public offering has Athersys selling 10,937,500 shares of ATHX stock for a

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX), today announced the pricing of its “reasonable best efforts” public offering of 10,937,500 shares of common stock (or common stock equiva

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announced financial result

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today the appointment of Neem

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today it wil

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announces patient enrollme